Sulpiride and Haloperidol in Schizophrenia: A Double-blind Cross-over Study of Therapeutic Effect, Side Effects and Plasma Concentrations

@article{Gerlach1985SulpirideAH,
  title={Sulpiride and Haloperidol in Schizophrenia: A Double-blind Cross-over Study of Therapeutic Effect, Side Effects and Plasma Concentrations},
  author={Jes Gerlach and Kirsten Behnke and Jon Heltberg and E. Munk‐Andersen and Henrik Nielsen},
  journal={British Journal of Psychiatry},
  year={1985},
  volume={147},
  pages={283 - 288}
}
Summary In a double-blind cross-over trial, 20 chronic schizophrenic patients were treated with sulpiride and haloperidol in two 12-week periods. The final median dose of sulpiride was 2000 mg/day (range 800–3200) and of haloperidol 12 mg/day (range 6–24). Sulpiride had an antipsychotic effect and therapeutic profile not significantly different from that of haloperidol. In spite of the high doses of sulpiride, extrapyramidal side-effects were seen less frequently during the first four weeks of… 
View on Cambridge Press
ncbi.nlm.nih.gov
77 Citations
Background Citations
4
Methods Citations
1
Results Citations
1

77 Citations

Remoxipride and haloperidol in schizophrenia: a double‐blind multicentre study.

Severe extrapyramidal side effects in the haloperidol group and clinical ineffectiveness in the remoxipride group were the most frequent reasons for premature discontinuation of treatment.

Haloperidol blood levels and clinical effects.

The results imply that low or moderate doses of neuroleptics are appropriate for many acutely psychotic patients.

Effect of haloperidol and (−)-sulpiride on dopamine agonist-induced hypoactivity

Serum haloperidol concentration and clinical response in schizophrenia.

It is suggested that in most cases there is no clinical advantage to the use of haloperidol doses greater than approximately 30 mg/day in schizophrenic patients.

The Relationship Between Serum Concentration and Therapeutic Effect of Haloperidol in Patients with Acute Schizophrenia

This article aims to provide a comprehensive review of the study design of studies in patients with acute schizophrenia before the study data are used for decision-making, and recommends serum concentration assay of haloperidol for investigations of nonresponse to exclude patients with pseudo-drug resistance.

A Risk-Benefit Assessment of Sulpiride in the Treatment of Schizophrenia

Sulpiride could find its specific therapeutic role in elderly patients with schizophrenia, as it shows a good margin of safety between therapeutic dosages and toxic concentrations, and its low incidence of extrapyramidal adverse effects.

Haloperidol blood levels and clinical outcome: a meta‐analysis of studies relevant to testing the therapeutic window hypothesis

The data support the existence of a therapeutic window between 4 and 26 ng/ml for haloperidol in the treatment of schizophrenic, schizoaffective and schizophreniform disorders.

Sulpiride and perphenazine in schizophrenia

Sulpiride appeared to be somewhat more effective than perphenazine for treatment of acute schizophrenia and Efficacy of both compounds was less marked in chronic forms of schizophrenia.

Neuroleptic treatment induces region-specific changes in levels of neurokinin a and substance P in rat brain

Future treatment of schizophrenia.

  • J. Gerlach
  • Psychology, Medicine
    Psychopharmacology series
  • 1988
During the search for new antipsychotic drugs, one must not forget to improve the practical use of available neuroleptics and of nonpharmacological, psychosocial treatment modalities.
...

References

SHOWING 1-10 OF 24 REFERENCES

Controlled Trial of Sulpiride in Chronic Schizophrenic Patients

The results show that sulpiride has neuroleptic properties and a spectrum of therapeutic activity similar to that of trifluoperazine.

Clinical Evaluation of Sulpiride in Schizophrenic Patients ‐ A Double‐blind Comparison with Chlorpromazine

A double‐blind study was performed comparing fixed doses of sulpiride and chlorpromazine for the treatment of schizophrenic patients, and interrater reliabilities for CPRS items and subscales were satisfactory.

Repeated administration of sulpiride for three weeks produces behavioural and biochemical evidence for cerebral dopamine receptor supersensitivity.

An evaluation of a unique new antipsychotic agent, sulpiride: effects on serum prolactin and growth hormone levels.

It appears that central dopaminergic blockade in the hypothalamic area is not a prerequisite for antipsychotic activity and sulpiride has a low potential for producing tardive dyskinesia.

Effects of Sulpiride on Persistent Neuroleptic‐induced Dyskinesia in Monkeys

Five Cebus apella monkeys with persistent neuroleptic-induced dyskinesia were given a single dose of sulpiride and four developed attacks of acute dystonia which had to be reversed by anticholinergic medication in three animals.

Effects of Sulpiride on Persistent Neuroleptic‐induced Dyskinesia in Monkeys

  • J. Häggström
  • Psychology, Medicine
    Acta psychiatrica Scandinavica. Supplementum
  • 1984
The dyskinesia was reduced in all five Cebus apella monkeys although four developed attacks of acute dystonia which had to be reversed by anticholinergic medication in three animals.

Comparison of sulpiride and chlorpromazine in psychoses

In a material of 71 patients admitted because of acute or chronic psychoses, 32 patients treated with sulpiride and 39 with chlorpromazine, the effect of the two preparations was very similar as were the type and frequency of side effects, except that sulpirides did not cause sunrash.

Sulpiride in Tardive Dyskinesia

The pathogenesis of tardive dyskinesia appears to consist of a combination of a predisposing vulnerability of the patient and an antidopaminergic treatment and in long‐term treatment, degenerative phenomena leading to a decreased threshold for expressing dyskinetic symptoms.

Diagnostic criteria for use in psychiatric research.

Diagnostic criteria for 14 psychiatric illnesses along with the validating evidence for these diagnostic categories comes from workers outside the authors' group as well as from those within; it consists of studies of both outpatients and inpatients, of family studies, and of follow-up studies.

The Brief Psychiatric Rating Scale

A substantial, specific abnormality in CSPG expression by astrocytes is pointed out that may contribute disruption of the function of neurones and glial cells of the amygdala and the entorhinal cortex in schizophrenia.